Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Sensitization of TRPA1 by PAR2 contributes to the sensation of inflammatory pain
Yi Dai, … , Hiroki Yamanaka, Koichi Noguchi
Yi Dai, … , Hiroki Yamanaka, Koichi Noguchi
Published July 2, 2007
Citation Information: J Clin Invest. 2007;117(7):1979-1987. https://doi.org/10.1172/JCI30951.
View: Text | PDF | Corrigendum
Research Article Neuroscience

Sensitization of TRPA1 by PAR2 contributes to the sensation of inflammatory pain

  • Text
  • PDF
Abstract

Proinflammatory agents trypsin and mast cell tryptase cleave and activate PAR2, which is expressed on sensory nerves to cause neurogenic inflammation. Transient receptor potential A1 (TRPA1) is an excitatory ion channel on primary sensory nerves of pain pathway. Here, we show that a functional interaction of PAR2 and TRPA1 in dorsal root ganglion (DRG) neurons could contribute to the sensation of inflammatory pain. Frequent colocalization of TRPA1 with PAR2 was found in rat DRG neurons. PAR2 activation increased the TRPA1 currents evoked by its agonists in HEK293 cells transfected with TRPA1, as well as DRG neurons. Application of phospholipase C (PLC) inhibitors or phosphatidylinositol-4,5-bisphosphate (PIP2) suppressed this potentiation. Decrease of plasma membrane PIP2 levels through antibody sequestration or PLC-mediated hydrolysis mimicked the potentiating effects of PAR2 activation at the cellular level. Thus, the increased TRPA1 sensitivity may have been due to activation of PLC, which releases the inhibition of TRPA1 from plasma membrane PIP2. These results identify for the first time to our knowledge a sensitization mechanism of TRPA1 and a novel mechanism through which trypsin or tryptase released in response to tissue inflammation might trigger the sensation of pain by TRPA1 activation.

Authors

Yi Dai, Shenglan Wang, Makoto Tominaga, Satoshi Yamamoto, Tetsuo Fukuoka, Tomohiro Higashi, Kimiko Kobayashi, Koichi Obata, Hiroki Yamanaka, Koichi Noguchi

×

Figure 2

PAR2 agonists sensitize AITC- and cinnamaldehyde-activated currents in transfected HEK cells expressing hTRPA1 in a PLC-dependent manner.

Options: View larger image (or click on image) Download as PowerPoint
PAR2 agonists sensitize AITC- and cinnamaldehyde-activated currents in t...
Cells were perfused with AITC (100 μM) or cinnamaldehyde (500 μM) solution for 20 seconds in all experiments. (A) Electrophysiological response of a representative transfected HEK cell to AITC in the absence or presence of ruthenium red (RR; 100 μM). Voltage ramps from –120 to +100 mV (340 ms) were applied. The inset graph shows AITC-activated current density in the absence or presence of ruthenium red (**P < 0.001). (B) AITC-activated inward currents underwent strong tachyphylaxis, giving much smaller responses on repeated applications of AITC. The inset graph shows normalized currents in each AITC challenge (n = 6). Currents were normalized to the currents evoked initially by AITC. (C) AITC-activated currents were sensitized after perfusion for 60 seconds with solution containing 100 μM SL-NH2. However, this sensitization was not sustainable 180 seconds after SL-NH2 application. (D) SL-NH2–mediated potentiation of AITC-activated currents. AITC was reapplied 60 seconds after exposure to bath solution with or without SL-NH2 (SL; 10, 50, or 100 μM) or LR-NH2 (LR). Currents were normalized to values first induced by AITC application in the absence of SL-NH2 or LR-NH2. Cont, control group (preperfused with bath solution without SL-NH2 before reapplication of AITC). (E) Cinnamaldehyde-evoked TRPA1 currents were potentiated by SL-NH2 but not LR-NH2. (F) AITC-activated currents were potentiated by application of trypsin (50 nM). Holding potential (Vh) was –60 mV in all experiments. Numbers in parentheses indicate cells tested. *P < 0.05 versus control group; #P < 0.05 versus LR-NH2; unpaired Student’s t test.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts